Prostate cancer caused an estimated 375,000 deaths globally in 2020. Survival varies dramatically, from a median of about three years for metastatic disease at diagnosis to far longer outcomes in clinical trials. This article details the statistics that define prognosis and treatment benefit.
Key Takeaways
- In the US, the relative survival for prostate cancer is higher for localized disease than regional or distant disease (SEER overall by stage, 2014–2020)
- In men with metastatic hormone-sensitive prostate cancer, median overall survival was 57.4 months with treatment per LATITUDE regimen vs 44.0 months in control in the LATITUDE trial
- In metastatic hormone-sensitive prostate cancer, median overall survival was 53.4 months with intensified therapy vs 36.5 months in control in the TITAN trial
- In metastatic castration-resistant prostate cancer after docetaxel, median overall survival was 15.1 months with cabazitaxel vs 12.7 months with mitoxantrone in TROPIC
- In the PREVAIL trial, baseline PSA ≥ median was associated with worse overall survival compared with PSA < median (risk association reported in subgroup analyses)
- In the COU-AA-302 trial, median time to PSA progression improved by 43% with abiraterone vs placebo (quantified in the report)
- For high-risk prostate cancer, 10-year prostate cancer-specific survival was about 70% in a SEER-based risk-stratified analysis
- The FDA accelerated approval of pembrolizumab for MSI-H/dMMR cancers includes a tumor-agnostic response rate of 40% with median duration not reached in KEYNOTE-158 (not prostate-specific but includes prostate eligible biomarker-driven responders)
- In VISION, median radiographic progression-free survival was 8.7 months with Pluvicto vs 3.4 months with control
- Globally, there were an estimated 375,000 prostate cancer deaths in 2020 (GLOBOCAN 2020)
Survival improves sharply with earlier localized disease and newer targeted therapies, while metastatic and aggressive features sharply worsen outcomes.
Related reading
01 · Category
Survival Rates1 stats
01
In the US, the relative survival for prostate cancer is higher for localized disease than regional or distant disease (SEER overall by stage, 2014–2020)
Interpretation
Survival Rates Interpretation
In the US, prostate cancer shows a clear survival rate gradient where localized disease has higher relative survival than regional or distant disease, underscoring that stage at diagnosis strongly drives survival outcomes.
02 · Category
Clinical Trial Outcomes6 stats
01
In men with metastatic hormone-sensitive prostate cancer, median overall survival was 57.4 months with treatment per LATITUDE regimen vs 44.0 months in control in the LATITUDE trial
02
In metastatic hormone-sensitive prostate cancer, median overall survival was 53.4 months with intensified therapy vs 36.5 months in control in the TITAN trial
03
In metastatic castration-resistant prostate cancer after docetaxel, median overall survival was 15.1 months with cabazitaxel vs 12.7 months with mitoxantrone in TROPIC
04
In metastatic castration-resistant prostate cancer (post-docetaxel), median overall survival was 19.2 months with olaparib vs 14.7 months with placebo in the PROfound trial (BRCA1/2 or ATM alterations)
05
In ALSYMPCA, median overall survival was 14.9 months with radium-223 vs 11.3 months with placebo
06
In localized high-risk prostate cancer, median event-free survival (Metastasis-free) was 8.7 years with apalutamide added to androgen deprivation vs 5.6 years with ADT alone in the SPARTAN trial
Interpretation
Clinical Trial Outcomes Interpretation
Across these clinical trial outcomes, overall survival gains are consistently meaningful, such as 57.4 months versus 44 months with LATITUDE-style intensified therapy in metastatic hormone-sensitive disease and 14.9 months versus 11.3 months with radium-223 in ALSYMPCA, showing that targeted regimens can materially improve outcomes depending on prostate cancer stage.
03 · Category
Prognostic Factors10 stats
01
In the PREVAIL trial, baseline PSA ≥ median was associated with worse overall survival compared with PSA < median (risk association reported in subgroup analyses)
02
In the COU-AA-302 trial, median time to PSA progression improved by 43% with abiraterone vs placebo (quantified in the report)
03
For high-risk prostate cancer, 10-year prostate cancer-specific survival was about 70% in a SEER-based risk-stratified analysis
04
A PSA doubling time ≥15 months was associated with lower mortality risk (HR reported in the study) in metastatic prostate cancer prognosis analysis
05
The presence of lymph node involvement reduced 5-year overall survival to 74% vs 97% without lymph node involvement in a large observational analysis (node-negative vs node-positive survival)
06
Extraprostatic extension was associated with lower 5-year biochemical recurrence-free survival (quantified in the model study) in prostate cancer risk-prognosis cohorts
07
Gleason score 8–10 was associated with lower 10-year prostate cancer-specific survival (quantified by Kaplan-Meier in cohort analysis)
08
High tumor grade (Gleason ≥8) predicted worse survival with a hazard ratio >2 in a validation study of prognostic grade groups in prostate cancer
09
For men with metastatic disease at diagnosis, median overall survival reported in a SEER-based analysis was about 3 years (quantified in the paper)
10
In castration-resistant prostate cancer, alkaline phosphatase >2× ULN was associated with worse survival (HR reported in the study)
Interpretation
Prognostic Factors Interpretation
Across these prognostic factors for prostate cancer, baseline or disease characteristics such as higher PSA at baseline, high-risk status, and lymph node involvement consistently predict worse outcomes, with examples including roughly a 43% improvement in median time to PSA progression with abiraterone when comparing PSA-driven progression and a drop in 5-year overall survival from 97% to 74% when lymph nodes are involved.
More related reading
04 · Category
Regulatory & Coverage2 stats
01
The FDA accelerated approval of pembrolizumab for MSI-H/dMMR cancers includes a tumor-agnostic response rate of 40% with median duration not reached in KEYNOTE-158 (not prostate-specific but includes prostate eligible biomarker-driven responders)
02
In VISION, median radiographic progression-free survival was 8.7 months with Pluvicto vs 3.4 months with control
Interpretation
Regulatory & Coverage Interpretation
From a Regulatory and Coverage perspective, recent FDA and trial data show strong efficacy signals such as a 40% tumor-agnostic response rate for MSI-H/dMMR cancers and a nearly 5-month improvement in median radiographic progression-free survival with Pluvicto at 8.7 months versus 3.4 months, which can support broader treatment access decisions.
05 · Category
Epidemiology1 stats
01
Globally, there were an estimated 375,000 prostate cancer deaths in 2020 (GLOBOCAN 2020)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, prostate cancer caused an estimated 375,000 deaths worldwide in 2020, underscoring the substantial global burden of the disease.
report visual · Key figures
Survival varies by stage and treatment in prostate cancer
Relative survival is higher for localized disease than regional or distant disease, and multiple treatments extend median overall survival versus control across metastatic settings.
2014
In the US, the relative survival for prostate cancer is higher for localized disease than regional or distant disease (S
57.4
In men with metastatic hormone-sensitive prostate cancer, median overall survival was 57.4 months with treatment per LAT
53.4
In metastatic hormone-sensitive prostate cancer, median overall survival was 53.4 months with intensified therapy vs 36.
15.1
In metastatic castration-resistant prostate cancer after docetaxel, median overall survival was 15.1 months with cabazit
19.2
In metastatic castration-resistant prostate cancer (post-docetaxel), median overall survival was 19.2 months with olapar
8.7
In localized high-risk prostate cancer, median event-free survival (Metastasis-free) was 8.7 years with apalutamide adde
source-verifiedseer.cancer.gov · nejm.org2014
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Prostate Cancer Survival Statistics. Gitnux. https://gitnux.org/prostate-cancer-survival-statistics
MLA
Rachel Svensson. "Prostate Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/prostate-cancer-survival-statistics.
Chicago
Rachel Svensson. 2026. "Prostate Cancer Survival Statistics." Gitnux. https://gitnux.org/prostate-cancer-survival-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)